Drugs / Inactivated poliomyelitis vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06101173 Comparator | Jan → Mar 2024 | poliomyelitis | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated poliomyelitis vaccine | “Inactivated poliomyelitis vaccine (IPOL)” NCT06101173 ↗ |
| Known as | IPOL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101173 ↗ |
| Modality | Vaccine | “Inactivated poliomyelitis vaccine” NCT06101173 ↗ |
| Route | Intramuscular | “Intramuscular injection (IM)” NCT06101173 ↗ |